BERLIN and BURLINGTON, Mass. – caprotec bioanalytics GmbH announced today the appointment of Marc Voigt as Managing Director, Chief Financial Officer and Chief Operating Officer.

Mr. Voigt joins caprotec from Medical Enzymes AG where he served as Chief Financial Officer and Chief Business Officer. Previous to that, he was Chief Financial Officer and Chief Business Officer at Revotar Biopharmaceuticals AG.

“Mr. Voigt is a well-known and respected executive in the biotech industry. He brings to caprotec strategic finance expertise and broad experience in biotech,” said caprotec founder and CEO Prof. Dr. Hubert Koster. “We are delighted to have him join caprotec’s management team as his strategic perspective will aid the growth of the company and is complimentary to caprotec’s current executive management team.”

“caprotec’s exciting CCMS has the potential to address one of the most daunting issues of the drug development process: the high late-stage attrition,” said Mr. Voigt. “I’m delighted to join the management team of caprotec and participate in the growth of this company that promises to have an important economic and financial impact in the pharmaceutical industry.”

caprotec’s executive management team is now comprised of Prof. Dr. Hubert Koster, founder and CEO, Prof. Dr. Rainer Metternich, CSO and CBO, and Mr. Voigt, CFO and COO. Dr. Koster is a renown serial entrepreneur who founded Biosyntech, Germany’s first biotech company, co-founded Milligen/Biosearch, the former biotech division of Millipore Corporation, and founded Sequenom, Inc. that achieved the third most subscribed biotech IPO on NASDAQ. Dr. Metternich previously held executive positions at Novartis, Schering AG and Merck & Co., and brings to caprotec broad expertise in drug development and a strong international network within the pharmaceutical industry. Mr. Voigt will complement the management team with his comprehensive financial and operational experience.

Mr. Voigt has held management positions in a number of biotech and technology investment companies in Europe. Prior to his executive management positions at Revotar Biopharmaceuticals AG and later at Medical Enzymes AG, Mr. Voigt was an investment manager for Mediport Ventures Fund. Before this, he worked in business development and managed IPOs for the investment bank net.IPO.AG in Frankfurt and was assistant to a member of the Executive Board of Allianz AG group. Mr. Voigt earned a Masters Degree in Business Administration from the Freie Universitat of Berlin.

About caprotec bioanalytics GmbH

caprotec bioanalytics is headquartered in Berlin, Germany with a US subsidiary in Burlington, MA. The company focuses on the commercialization of its proprietary Capture Compound Mass Spectrometry™ (CCMS) technology. The core of the CCMS technology consists of small, tri-functional molecules called Capture Compounds (CCs). They enable a targeted isolation of proteins directly from complex biological samples such as lysates, sub-cellular fractions or even intact whole cells. After isolation, the captured proteins including membrane proteins are identified and characterized by mass spectrometry. Providing a state-of-the-art platform for the isolation and analysis of proteins from complex mixtures by functional reduction of proteome complexity, the CCMS technology has enormous potential in proteomics, drug development and the development of protein biomarkers. The technology is validated by several publications in leading peer-reviewed scientific journals and is protected by a broad patent portfolio. The company is supported by an international scientific advisory board including one Nobel Laureate. The company is financed by LBBW Venture Capital GmbH, Creathor Venture, IBB Beteiligungsgesellschaft, ERP Startfonds, and well-known private investors.

SOURCE caprotec bioanalytics